An independent editorial review of how Fridays handles tirzepatide, why the GIP/GLP-1 dual agonist differs from single-receptor drugs, how the program prices it month to month, and the pathway-level genetic context in FTO, MC4R, and TCF7L2 a script cannot see.

An independent editorial look at how Fridays handles the semaglutide molecule specifically, from compounded-versus-branded sourcing to month-to-month pricing, plus the pathway-level genetic context in FTO, MC4R, and TCF7L2 that no semaglutide prescription measures on its own.

An independent review of Fridays' GLP-1 program covering its telehealth-plus-compounding model, the eligibility and prescription flow, the pricing published on its own page, and the pathway-level genetic context that Fridays and every other subscription leaves unread, before weighing it against a genetics-first alternative for context.